Colitis, Ulcerative Clinical Trial
Official title:
A Blinded Comparison of Conventional Colonoscopy to Endoscopic AFI and NBI for Dysplasia Detection in Patients With Ulcerative Colitis and Sclerosing Cholangitis or Known Colorectal Dysplasia or Cancer- A Pilot Clinical Study
This study is being done to:
To attempt to increase the detection of precancerous colon tissue in patients with chronic
ulcerative colitis and primary sclerosing cholangitis;
To determine if an investigational scope that can look at the lining of the colon in
different ways will help the doctor identify abnormal tissue in patients with chronic
ulcerative colitis and concurrent primary sclerosing cholangitis; and
To determine if this investigational scope can accurately detect precancerous or cancerous
tissue in patients with chronic ulcerative colitis that are known to have had cancerous or
precancerous tissue in the past.
Patients with concurrent chronic ulcerative colitis and primary sclerosing cholangitis or
patients with chronic ulcerative colitis and known colorectal dysplasia or cancer,
presenting for surveillance colonoscopy will be recruited. After giving informed consent
patients will then undergo colonoscopy in a segmental fashion. Colonoscopy with white light
will be performed to the cecum and examination will be performed on withdrawal. First
conventional white light will be used to examine the cecum and ascending colon and random
biopsies will be obtained. All endoscopically apparent lesions will be biopsied separately.
Immediately following will be examination of that segment of cecum and ascending colon under
AFI first, then NBI with targeted biopsies of suspicious areas being taken. The AFI and NBI
modality will be achieved by simply flipping a switch.. If necessary, washing of oozing
blood from random biopsy sites will be performed., The remainder of the colon will be
assessed in like fashion: transverse, descending and rectosigmoid. Because high definition
endoscopy is the default modality, this will be in use throughout the procedure.
All lesions detected will be documented and biopsied for a maximum of four biopsies per
suspicious lesion. Note will be taken of which modality resulted in visualization of the
lesion. Data on the factors under study will be collected: i) disease type (CUC + PSC or CUC
with known dysplasia), ii) Age, iii) Sex, iv) length of time with disease, v) extent of
disease, vi) the interaction between iv and v will be collected. In addition, dysplasia
yes/no will be established after biopsy histology is established and the modality under
which abnormalities were observed will also be recorded.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Completed |
NCT03494764 -
Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares
|
Phase 2 | |
Recruiting |
NCT03937609 -
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
|
Phase 4 | |
Completed |
NCT00503243 -
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT02537210 -
Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis
|
N/A | |
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT00488631 -
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT00928681 -
A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT05242484 -
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT01036022 -
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT03841045 -
Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
|
||
Active, not recruiting |
NCT05528510 -
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT02825914 -
CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)
|
N/A | |
Recruiting |
NCT06049017 -
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT04567628 -
Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
|
||
Withdrawn |
NCT05999708 -
A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT05611671 -
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
|
Phase 2 | |
Active, not recruiting |
NCT03596645 -
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03648541 -
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
|
Phase 2 |